Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

67 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-07-31

Study Completion Date

2014-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare a low dose oral contraceptive (OC) given continuously (every day for three months) with the same low dose oral contraceptive given in an interrupted regimen (one week of inactive placebo pills each month) and with continuous placebo (inactive placebo given every day for three months). The primary hypothesis is that continuous OC will be significantly more effective in reducing premenstrual symptoms compared with either the interrupted OC or continuous placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Ovarian Hormone Withdrawal, Anhedonia, and Reward Sensitivity in Women With Premenstrual Exacerbations of Depression

NCT06610305

Major Depressive Disorder

RECRUITING PHASE4

The Pill Project - Oral Contraceptive and Serotonergic Brain Signaling

NCT05212389

Major Depressive Disorder Sexual Behavior Mood Disturbance +4 more

UNKNOWN NA

Combined Hormone Replacement in Menstrually-Related Mood Disorders

NCT00005011

Premenstrual Syndrome Depression

COMPLETED

Stress Reactivity and Hormonal Contraception

NCT06223126

Hormonal Contraception

ENROLLING_BY_INVITATION

Study of Premenstrual Syndrome and Premenstrual Dysphoria

NCT00001177

Mood Disorder

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Premenstrual Dysphoric Disorder (PMDD) describes the cyclic appearance of affective symptoms and resultant impairment during the luteal phase of the menstrual cycle. The objective of this trial is to determine if extended oral contraceptive (OC) regimens with eliminated pill-free intervals will successfully prevent the expression of PMDD symptoms. The central hypothesis of this application is that continuous administration of OCs will minimize the destabilizing effects of changing reproductive steroid levels and prevent PMDD symptom emergence. The cause of PMDD is unknown, the morbidity substantial, and the identified treatments limited in their effectiveness, since 40% of PMDD women are non-responders to elective serotonin re-uptake inhibitors (SSRIs). Earlier controlled studies of OCs to treat PMDD failed to find OCs superior to placebo using the traditional 21/7 platform (21 active pills followed by a 7 day pill-free interval (PFI)). Two recent trials of a low dose OC using a 24/4 platform did report greater reductions in premenstrual symptoms relative to placebo, presumably due to the shortened PFI. Despite the apparent efficacy of the 3-day extended dosing of this OC, the placebo response rate was substantial in these studies, resulting in a low effect size. Moreover, no steroid hormone levels were examined in these prior studies. In the absence of hormonal data, inferences about the mechanism of efficacy of extended OCs must remain speculative and untested.

Our proposed research will addresses the critical role of hormonal change in the precipitation of PMDD symptoms before and after treatment with a continuous OC regimen, an interrupted OC regimen (21/7 platform) and continuous placebo. This study will also permit us to examine the role of neurosteroids in PMDD. While acting acutely as anxiolytic positive modulators of the gamma-aminobutyric acid A (GABAA) receptor, these neurosteroids may paradoxically reduce the response of the GABAA receptor and cause irritability (in rats) following either extended exposure or withdrawal. Further, our prior research suggests that elevated levels of or changes in peripheral neurosteroid levels are associated with dysphoric mood symptoms in women with PMDD. Our hypothesis is that changes in neurosteroids modulate symptom severity rather than appearance in PMDD. The results of our study will suggest therapeutic targets and will inform future studies of both PMDD and related affective disorders.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Premenstrual Dysphoric Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Continuous OC (EE/DROS)

Continuous daily oral drospirenone (DROS; 3mg) + ethinyl estradiol (EE; 20ug)

Group Type ACTIVE_COMPARATOR

Continuous OC (EE/DROS)

Intervention Type DRUG

Continuous EE(20ug)+DROS(3mg) daily for 3 months

Intermittent OC (EE/DROS)

Interrupted (21 days active - 7 days placebo) oral DROS (20ug)/EE(3mg)

Group Type ACTIVE_COMPARATOR

Intermittent OC (EE/DROS)

Intervention Type DRUG

Intermittent EE(20ug)+DROS(3mg) daily for 21 days each month

Placebo

Continuous daily oral placebo

Group Type PLACEBO_COMPARATOR

placebo

Intervention Type DRUG

daily placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Continuous OC (EE/DROS)

Continuous EE(20ug)+DROS(3mg) daily for 3 months

Intervention Type DRUG

Intermittent OC (EE/DROS)

Intermittent EE(20ug)+DROS(3mg) daily for 21 days each month

Intervention Type DRUG

placebo

daily placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Yaz Yaz oral placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* meets prospective criteria for PMDD, AND
* English speaking and reading skills.

Exclusion Criteria

* current psychiatric disorder other than PMDD,
* history of venous thromboembolism,
* over 35 years of age and obese,
* uncontrolled hypertension or end-organ vascular disease,
* diabetes,
* migraine headache with aura,
* breastfeeding or pregnant,
* cigarette smoking,
* family history of premenopausal breast cancer or breast cancer in more than one first degree relative,
* elevated serum potassium levels, use of prescription medications (except stable thyroid supplementation),
* irregular menstrual cycles, OR
* history of: endometriosis, hepatic disease, breast carcinoma, pulmonary embolism or phlebothrombosis, malignant melanoma, cholecystitis or pancreatitis.

Minimum Eligible Age

18 Years

Maximum Eligible Age

52 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No